Welcome to our dedicated page for HilleVax SEC filings (Ticker: HLVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HilleVax, Inc. (HLVX) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, including Forms 10-K, 10-Q, 8-K, 25 and 15, as filed with the U.S. Securities and Exchange Commission. These filings document HilleVax’s period as a Nasdaq-listed clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, particularly virus-like particle (VLP) based candidates such as HIL-214 and HIL-216 for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Investors and analysts can use periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q to review HilleVax’s historical financial statements, research and development spending, general and administrative expenses, and risk factor disclosures related to its norovirus vaccine programs. Current reports on Form 8-K capture material events, including announcements about clinical trial results, workforce reductions, strategic reviews, and the agreement and plan of merger with XOMA Royalty Corporation.
Filings in 2025 are particularly important for understanding the corporate transaction and change in listing status. A Form 8-K dated September 17, 2025, describes the completion of the tender offer and merger in which HilleVax became a wholly owned subsidiary of XOMA Royalty. A Form 25 filed on September 17, 2025, by The Nasdaq Stock Market LLC provides notification of the removal of HilleVax’s common stock from listing and registration under Section 12(b) of the Exchange Act. A subsequent Form 15 filed on September 29, 2025, certifies the termination of registration of the common stock under Section 12(g) and the suspension of HilleVax’s duty to file reports under Sections 13 and 15(d).
On Stock Titan, users can view these documents in sequence and rely on AI-powered summaries that highlight key points from lengthy filings, such as the terms of the merger, the structure of the contingent value right, and the implications of delisting and deregistration. This makes it easier to interpret how HilleVax’s regulatory history reflects its evolution from a standalone public issuer to a subsidiary of XOMA Royalty, and how its norovirus vaccine programs were described in official SEC disclosures.
XOMA Royalty Corporation ("Parent") and wholly-owned subsidiary XRA 4 Corp. ("Merger Sub") have filed a Schedule TO-C announcing their intent to launch a third-party tender offer to acquire 100 % of the outstanding common shares of HilleVax, Inc. (HLVX). The offer will be effected pursuant to an Agreement and Plan of Merger dated 4 Aug 2025; however, no tender has yet commenced and no price, premium or timing details are disclosed in this preliminary communication.
When the offer begins, the Buyer Entities will file a full Schedule TO and HilleVax will respond with a Schedule 14D-9. Shareholders are advised to await those materials, which will be available free of charge on the SEC’s website. The filing reiterates standard forward-looking-statement cautions and lists numerous risks that could prevent closing, including regulatory approvals, competing bids and litigation.
HilleVax, Inc. (HLVX) – Form 4 filing dated 06/25/2025
Non-employee director Patrick J. Heron reported the receipt of 17,199 Restricted Stock Units (RSUs) on 06/23/2025 at a cost basis of $0.00. The award was made under the company’s Non-Employee Director Compensation Program.
- Vesting: 100% on the earlier of (i) 06/23/2026 or (ii) a Change in Control, subject to continued board service.
- Post-transaction direct holdings: 17,199 shares.
- Indirect holdings: 8,535,337 shares held through Frazier Life Sciences X, L.P., for which Mr. Heron shares voting and investment control.
No derivative securities were reported. The filing represents routine director equity compensation rather than open-market activity and does not involve the sale or disposal of shares.
HilleVax, Inc. (HLVX) filed a Form 4 disclosing that non-employee director Shelley Chu received 17,199 shares of common stock in the form of Restricted Stock Units (RSUs) on 23 June 2025. The RSUs were awarded under the company’s 2022 Incentive Award Plan as part of the Non-Employee Director Compensation Program. The filing shows the transaction was coded “A” (acquisition) at a price of $0.00, confirming it was a grant rather than an open-market purchase.
The RSUs will vest 100 % on the earlier of (i) the first anniversary of the grant date or (ii) a Change in Control, provided Dr. Chu remains on the board until the applicable vesting date. Following the grant, Dr. Chu’s total beneficial ownership stands at 17,199 shares, held directly. No derivative securities were reported, and there were no dispositions.
The filing is routine director equity compensation, adding a small amount of potential dilution but primarily aligning the director’s interests with shareholders. No cash consideration, purchase of shares, or sales were reported, and the filing contains no financial performance metrics or strategic commentary.
FAQ
What is the current stock price of HilleVax (HLVX)?
What is the market cap of HilleVax (HLVX)?
